A Modeling Framework to Characterize Cytokine Release upon T‐Cell–Engaging Bispecific Antibody Treatment: Methodology and Opportunities-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Modeling Framework to Characterize Cytokine Release upon T‐Cell–Engaging Bispecific Antibody Treatment: Methodology and Opportunities

Published:2019-07-26 Issue:6 Volume:12 Page:600-608
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Chen Xiaoying¹,Kamperschroer Cris²,Wong Gilbert³,Xuan Dawei¹

Affiliation:

1. Early Oncology Development and Clinical Research Pfizer San Diego California USA

2. Drug Safety Research and Development Groton Connecticut USA

3. Early Oncology Development and Clinical Research Pfizer South San Francisco California USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12662

Reference28 articles.

1. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics

2. Current concepts in the diagnosis and management of cytokine release syndrome

3. Cytokine release syndrome: Who is at risk and how to treat

4. Blinatumomab: A historical perspective

5. Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of statistical methods for biomarkers relevant to early clinical development of cancer immunotherapies;Frontiers in Immunology;2024-08-21

2. Coupling quantitative systems pharmacology modelling to machine learning and artificial intelligence for drug development: its pAIns and gAIns;Frontiers in Systems Biology;2024-07-12

3. Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T‐Cell Engager, Using Population Pharmacokinetics and Exposure–Response Analysis;Clinical Pharmacology & Therapeutics;2024-06-28

4. Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology;Clinical Pharmacology & Therapeutics;2024-06-02

5. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis;Clinical Pharmacology & Therapeutics;2024-03-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3